Clinical Trial Update: Allogeneic CD19-CAR-NK Cells in Patients With Refractory Myasthenia Gravis [EARLY_Phase 1]

View source ↗

Summary

This update describes an early-phase trial evaluating allogeneic CD19-CAR-NK cells for refractory myasthenia gravis, with the study currently not yet recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• Allogeneic CD19-CAR-NK cells (CD19-CAR-NK cells)

Snippet

Sponsor: Guangdong ProCapZoom Biosciences Co., Ltd. | Conditions: Refractory Myasthenia Gravis | EARLY_Phase 1 | Status: NOT_YET_RECRUITING